Mimedx (MDXG) Cash from Operations Growth (3y) (2014 - 2026)
Mimedx (MDXG) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 34.32% |
| 10 | Mimedx | 645.74 Mn | 485.97 Mn | 41.62 Mn | 46.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.30% |
| Dec 31, 2025 | 79.75% |
| Sep 30, 2025 | 212.72% |
| Jun 30, 2025 | 89.44% |
| Mar 31, 2025 | 36.05% |
| Dec 31, 2024 | 54.51% |
| Sep 30, 2024 | 48.08% |
| Jun 30, 2024 | 138.94% |
| Mar 31, 2024 | 42.52% |
| Dec 31, 2023 | 28.22% |
| Sep 30, 2023 | 69.12% |
| Jun 30, 2023 | 80.33% |
| Mar 31, 2023 | 27.01% |
| Dec 31, 2022 | 29.78% |
| Sep 30, 2022 | 32.07% |
| Jun 30, 2022 | -50.53% |
| Mar 31, 2022 | 12.50% |
| Dec 31, 2021 | -109.93% |
| Sep 30, 2021 | 23.06% |
| Jun 30, 2021 | -57.40% |